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vThe beneficial effect of lowering low-density lipoprotein
cholesterol (LDL-C) in clinical trials (1) has transformed
our ability to reduce cardiovascular risk. However, increas-
ing recognition that many patients experience a clinical
event, despite the use of LDL-C lowering therapies, has
stimulated the ongoing search to develop additional thera-
peutic strategies. Although elevated levels of triglycerides
and lipoprotein(a) independently predict cardiovascular
events (2,3), to the author’s knowledge, no clinical trial to
date has demonstrated that any therapy that specifically
targets either of these factors is associated with cardiovas-
cular benefit.
High-density lipoprotein cholesterol (HDL-C) has re-
ceived considerable interest with respect to potential cardio-
vascular protection. Population studies consistently demon-
strate an inverse relationship between HDL-C levels and
prospective cardiovascular risk (4), which has prompted the
concept that substantially increasing HDL-C would be
beneficial. Preclinical studies demonstrating favorable ef-
fects of HDL-C–based interventions in cellular and animal
models provide further support for the interest in develop-
ing therapies that increase HDL-C (5). However, current
lipid-modifying approaches typically have modest effects on
HDL-C.
Niacin as a Viable Therapeutic Option
For 50 years, niacin has been used in clinical practice for
the management of dyslipidemia. Niacin remains the most
effective HDL-C increasing agent available in clinical prac-
tice and is often used in patients with very low HDL-C
levels. It is also widely used by virtue of its ability to lower
levels of atherogenic lipid parameters in patients with mixed
dyslipidemia, suboptimal LDL-C control, or statin intoler-
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and protective lipids are further supported by evidence that
early formulations of niacin had a favorable cardiovascular
impact. The Coronary Drug Project, conducted in the
pre-statin era, demonstrated that use of immediate-release
forms of niacin decreased the rates of nonfatal myocardial
infarction and long-term mortality (6).
Subsequent imaging studies demonstrated that immediate-
release forms of niacin produced mild, but significant,
regression of coronary atherosclerosis on angiography (7),
hereas more extended release formulations had a favorable
mpact on the progression of carotid intima–medial thick-
ess (8,9). More recent studies using magnetic resonance
maging demonstrated similarly beneficial effects of niacin
n carotid atherosclerosis in some (10), but not all (11),
tudies. The findings of these studies provide a strong
ationale for determining the potential role of niacin in the
tatin era.
he AIM-HIGH Trial
he AIM-HIGH (Atherothrombosis Intervention in Met-
bolic Syndrome With Low HDL/High Triglycerides:
mpact on Global Health Outcomes) trial evaluated the
mpact of extended-release niacin versus placebo in patients
ith established atherosclerotic disease on statin therapy,
ith a background of low HDL-C and high triglyceride
evels (12). At the time of a planned interim analysis, after
n average of 3 years of treatment, the Data Safety and
onitoring Board recommended early cessation of the
tudy due to the futility of the primary endpoint and a
otential increase in the risk of stroke. Predictably, the
iacin group demonstrated a greater increase in HDL-C
25.0% vs. 9.8%) and decrease in triglycerides (28.6% vs.
.1%) and LDL-C (12.0% vs. 5.5%), the latter despite the
se of an LDL-C algorithm, resulting in more placebo-
reated patients requiring increases in statin dose or the
ddition of ezetimibe. A nearly identical number of cardio-
ascular events was observed in both treatment groups.
lthough a greater number of ischemic strokes was recorded
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cessation of therapy, this ultimately did not meet statistical
significance. The results demonstrated unequivocally no
signal of potential benefit in the niacin group.
Challenges for Interpreting AIM-HIGH
Although AIM-HIGH was stopped in May 2011, the
formal results were not revealed until November. This
permitted considerable time for widespread speculation of
the reasons underlying the failure of efficacy and potential
mechanisms leading to an increase in stroke risk. This
included media coverage and uncertainty in clinical practice
whether to continue use of niacin for cardiovascular risk
prevention. Now that the definitive findings of the study
have been revealed, how should they be interpreted for the
management of patients with dyslipidemia? To do this, one
must determine what the real objective was of AIM-HIGH.
Given that the fundamental comparison was between
extended-release niacin and placebo, the easiest conclusion
would be that AIM-HIGHwas a test of the niacin hypothesis.
The overwhelming majority of data in niacin trials, using either
the immediate- or extended-release formulation, demon-
strated potential cardiovascular benefit. However, the clin-
ical event benefit was observed in the pre-statin era and
involved formulations that are poorly tolerated by many
patients. There is substantial interest in determining
whether a well-tolerated form of niacin is beneficial in the
setting where statin therapy has become almost ubiquitous.
However, AIM-HIGH was not a simple comparison of
niacin and placebo. In fact, the authors, appreciating that
niacin lowers atherogenic lipid parameters, used a lipid-
lowering algorithm to equilibrate LDL-C levels. What
eventuated was a comparison of niacin- and placebo-treated
patients who were more likely to be treated with ezetimibe
and higher doses of simvastatin. Furthermore, placebo-
treated patients actually received as much as 200 mg daily of
immediate-release niacin to induce flushing and maintain
the blind. The rationale for this action lay in the experience
that, although flushing occurs at low doses, beneficial effects
of niacin on lipids are typically not observed until doses of at
least 1,500 mg/day are administered. However, the possi-
bility that niacin had some favorable effects, reported by
some investigators (13), cannot be excluded. Therefore, it is
not possible to simply conclude that AIM-HIGH was a
straightforward arbiter of the potential cardiovascular ben-
efits of niacin. That remains the opportunity for a more
simply designed study.
The other factor implicated in the futility of AIM-
HIGH is increasing HDL-C. Niacin continues to be the
most effective HDL-C–increasing agent in clinical practice.
Considerable interest has focused on the potential benefit of
HDL-C–increasing therapies, based on findings from pop-
ulation and animal studies (4,5). This is of most importance
in the statin-treated patient whose HDL-C remains low,
with evidence that these patients have a substantial ongoingrisk of cardiovascular events (14). In many ways, such
observations underscored the selection of low HDL-C
patients in the AIM-HIGH trial. However, although a
number of reports suggest that a modest increase in
HDL-C may contribute to the benefits of statins and
fibrates, more recent high-profile failures in clinical trials of
fenofibrate (15), torcetrapib (16), and now niacin in the
AIM-HIGH trial provide further ammunition for those
skeptical of increasing HDL-C as a viable cardioprotective
strategy.
Was AIM-HIGH a true test of the HDL-C hypothesis?
The use of LDL-C equilibration strategies further aimed to
focus the spotlight on increasing HDL-C. However, the
final publication revealed an underwhelming result, with a
much smaller difference in HDL-C than expected in the 2
treatment groups. Although a greater increase in HDL-C
was observed with niacin, the absolute difference in achieved
HDL-C levels was only 4 mg/dl (42 vs. 38 mg/dl). This was
largely due to an unexpected increase in HDL-C by 9.8% in
the placebo group. Although the reason for this is uncertain,
it may reflect the use of higher statin doses, small doses of
immediate-release niacin, and potential regression to the
mean in these patients. Moreover, niacin has additional
effects, beyond its effects on HDL-C and LDL-C. Niacin
lowers triglycerides and is the most effective agent for
decreasing levels of lipoprotein(a). Whether these effects, in
addition to the reported favorable effects on endothelial
function, have further effects in these patients is uncertain,
but must be considered when seeking the rationale for
futility. Accordingly, it seems premature to attribute these
disappointing findings to a failure of the HDL hypothesis.
Although one should not throw the baby out with the
bathwater, the attempts to demonstrate the potential benefit
of increasing HDL-C will be limited. The clock continues
to tick.
The ultimate question when interpreting AIM-HIGH is
to ask whether the trial delivered the comparison that it
sought to carry out. The study endeavored to determine
whether niacin, which would increase HDL-C, would
decrease events in patients with atherosclerotic disease and
low HDL-C and high triglyceride levels, when LDL-C
levels were kept at comparable levels in the 2 groups. The
study needed to enroll 3,414 patients to have 85% power to
demonstrate a 25% reduction in clinical events with niacin.
In the statin era with decreasing event rates, these sample-
size assumptions seemed overly optimistic. Many contem-
porary studies require well in excess of 10,000 patients to
demonstrate adequate power and target much more realistic
relative-risk reductions, on the order of 15%. Considering
that the achieved lipid levels demonstrated a small difference
between treatment groups in terms of both HDL-C (4
mg/dl) and LDL-C (5 mg/dl), the most optimistic relative-
risk reduction that one could predict would be closer to
10%. There is no doubt that AIM-HIGH demonstrated
unequivocal futility and should have been stopped, the
question being if the investigators knew at the outset what
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with the assistance of the faithful “retrospectoscope,” it
would appear that even an optimist would have to concede
that this was the wrong trial to answer the important
question that the investigators sought to answer.
Where to From Here?
AIM-HIGH is an important study with considerable im-
plications for physicians and clinical trialists. In this issue of
the Journal, Michos et al. (17) place the AIM-HIGH trial
in the context of previous studies of niacin and recent
high-profile failures of lipid-modifying therapies in statin-
treated patients. Before one embarks on trying to find some
clinical context for the findings, we need to ask whether the
study truly ended up meeting its initial objectives. For this,
the answer unfortunately has to be no. Herein lies the
difficulty of knowing when to accept and adopt the findings
of clinical trials. The randomized, clinical trial has guided
much of our practice over the course of the past 3 decades.
Unfortunately, trials do not always provide the clear answer
that we are looking for.
Do the findings change the way in which niacin is used in
clinical practice? For those who perceive the results as a
failure of niacin, they are likely to use this agent less for risk
reduction. For those who do not think that AIM-HIGH
proved a lack of efficacy of niacin, they will continue to use
it for its range of lipid-modifying effects, particularly in
those treated with maximally tolerated statin doses but are
still not at their LDL-C goal, and wait for the findings of
future clinical trials to make their ultimate decision. The
HPS2-THRIVE (Treatment of HDL to Reduce the Inci-
dence of Vascular Events) study is designed to directly
compare the effects of the combination of extended-release
niacin and the prostaglandin receptor antagonist laropiprant
with those of placebo, and no in-study titration of LDL-C,
in 24,000 statin-treated patients (18). It would seem that
this trial represents a more adequately powered and simple
study to determine whether the use of niacin is efficacious in
the setting of statin therapy.
However, the findings of AIM-HIGH do add to a
mounting challenge for those developing new antiathero-
sclerotic therapies. LDL-C lowering, particularly with st-
atins, has had a profound impact on cardiovascular event
rates. We highlight the ongoing occurrence of events as the
rationale to develop new therapies, yet, to date, we have
failed to demonstrate that any new strategy has a favorable
outcome on a background of statin therapy. Does this imply
that we have come to the end of the road in terms of
reducing cardiovascular risk, when patients achieve effective
LDL-C lowering, perhaps? Is it possible that much of the
residual risk that we highlight is not modifiable? Or perhaps
do we need to identify alternative targets for modification?
That remains the focus for future clinical trials, and for that
reason, we continue to believe that we can further reduce the
burden of cardiovascular disease.Reprint requests and correspondence: Dr. Stephen J. Nicholls,
Department of Cardiovascular Medicine, Mail Code JJ-65, Cleve-
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